12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday’s regular session. The company’s market…
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares rose 60.2% to $0.27 during Wednesday’s pre-market session. The market value of their…
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday’s session after the company reported worse-than-expected FY24 financial results…
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday’s regular session. The company’s market…
Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Tuesday. Shares of Patterson…
Boston Scientific Adds Stroke Prevention To Vascular Portfolio Via Silk Road Medical’s $1.3B Deal
Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR system, a breakthrough in stroke prevention. Transaction closes in H2 2024.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 63.8% to $0.28 during Tuesday’s pre-market session. The company’s market cap…
Evaluating Silk Road Medical: Insights From 6 Financial Analysts
Ratings for Silk Road Medical (NASDAQ:SILK) were provided by 6 analysts in the past three months, showcasing a…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) shares rose 11.1% to $0.99 during Tuesday’s after-market session. The market value of their…
Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO’s Initiatives Sets Stage For ‘Back On Track’
Stifel's upgraded outlook on Silk Road Medical as CEO Chas McKhann addresses concerns, unveils a compelling vision, and outlines strategic initiatives. Analysts upgrade to Buy with $20 price target, citing confidence in TCAR technology and long-term growth under McKhann's leadership.